Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

Tel Aviv University researcher discovers homing device that draws cancer

The process of metastasis, by which cancer cells travel from a tumor site and proliferate at other sites in the body, is a serious threat to cancer patients. According to the National Cancer Institute, most recurrences of cancer are metastases rather than "new" cancers.

20 Sep 2012

RRM2 may be a facilitating factor in colorectal cancer and UV-induced DNA damage repair

Colorectal cancer (CRC) is the leading cause of cancer-related death worldwide. In addition, the incidence and mortality rates of colorectal cancer are on the rise. Recently, metabolic genes have received increasing and specific attention due to their potential role in carcinogenesis.

20 Sep 2012

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga®) offers a significant survival benefit to patients with castration-resistant prostate cancer, which is spreading to other parts of their body (known as metastatic prostate cancer).

18 Sep 2012

Power of taxane-based chemotherapy drugs may be potentially underestimated

The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.

18 Sep 2012

UMass Amherst develops 'chemical nose' array to detect metastatic cancers

In the fight against cancer, knowing the enemy's exact identity is crucial for diagnosis and treatment, especially in metastatic cancers, those that spread between organs and tissues. Now chemists led by Vincent Rotello at the University of Massachusetts Amherst have developed a rapid, sensitive way to detect microscopic levels of many different metastatic cell types in living tissue. Findings appear in the current issue of the journal ACS Nano.

14 Sep 2012

HIF-1a protein of hypoxia creates CD24 overexpression in many tumors

It seems as if a tumor deprived of oxygen would shrink. However, numerous studies have shown that tumor hypoxia, in which portions of the tumor have significantly low oxygen concentrations, is in fact linked with more aggressive tumor behavior and poorer prognosis.

14 Sep 2012

Optimal approach for esophageal cancer surgery varies

Accurate preoperative staging of junctional adenocarcinoma of the esophagus can impact the surgical approach used, and postoperative outcomes vary according to the patients’ stage of disease, report German researchers.

13 Sep 2012

FDG–PET/CT improves staging and modifies radiotherapy management

The addition of FDG–positron emission tomography/computed tomography revised radiotherapy decision-making and enhanced tumor staging capabilities in patients with non-small-cell lung cancer, research shows.

13 Sep 2012

HIF-1 activity directly responsible for spread of breast cancer to lymph vessels

The invasion of cancer cells into the lymph vessels that connect the breast to surrounding lymph nodes is the first step leading to the metastasis, or spread, of cancer throughout the body. Metastasis is the primary cause of breast cancer deaths. Surprisingly little is known about the control of this process and how it might be interrupted to prolong the lives of women with breast cancer.

11 Sep 2012

Insight into how tissue stiffness drives cancer

The stiffness of breast tissue is increasingly recognized as an important factor explaining the onset of breast cancer. Stiffening induces molecular changes that promote cancerous behavior in cells. Bioengineering studies have found that breast cancer cells grown on a 3-D gel have enhanced cell replication and decreased organization as rigidity increases.

10 Sep 2012

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer, today announced the online publication in Clinical Cancer Research of preclinical data demonstrating the potent anti-cancer activity of anti-DLL4 (demcizumab) in patient-derived pancreatic tumor models.

7 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

F-18-FDG PET/CT may easily predict disease-free survival for invasive ductal breast cancer patients

Disease-free survival for invasive ductal breast cancer (IDC) patients may be easier to predict with the help of F-18-fludeoxyglucose positron emission tomography (PET)/computed tomography (CT) scans, according to research published in the September issue of The Journal of Nuclear Medicine. New data show that high maximum standard uptake value (SUVmax) of F-18-FDG in the lymph nodes prior to treatment could be an independent indicator of disease recurrence.

6 Sep 2012

Sleep apnoea severity associated with increased cancer mortality

Sleep apnoea severity has been associated with increased cancer mortality in a new study.

5 Sep 2012

New strategy for outsmarting cancer through its own social intelligence

In the face of mounting evidence that cancer cells communicate, cooperate and even engage in collective decision-making, biophysicists and cancer researchers at Rice University, Tel Aviv University and Johns Hopkins University are suggesting a new strategy for outsmarting cancer through its own social intelligence.

5 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012